Mupirocin ointment application at the exit site of temporary central line hemodialysis catheters markedly reduces S. aureus bloodstream infections

Dialysis and Transplantation

Volumn 32, Issue 8, 2003, Pages 484-489+513

  Silverberg, D ^a   Stozenko, F ^a   Blum, M ^a   Tzion, S Ben ^a   Schwartz, D ^a   Yachnin, T ^a   Baruch, R ^a   Shaked, M ^a   Iaina, A ^a   Siegman Igra, Y ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE; DISINFECTANT AGENT; POVIDONE IODINE; PSEUDOMONIC ACID;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD CULTURE; CATHETER; CATHETER INFECTION; CATHETER RELATED BLOODSTREAM INFECTION; CENTRAL VENOUS CATHETER; DISINFECTION; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMODIALYSIS; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; VASCULAR ACCESS;

EID: 0042575273     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Work group of the NKF-K/DOQI. Clinical practice guidelines for vascular access. Am J Kidney Dis 2001; 37(Suppl 1):S137-S181.
2. Piraino B. Staphylococcus aureus infections in dialysis patients: Focus on prevention. ASAIO J 2000; 46:S13-S17.
3. Blankestijn PJ. Treatment and prevention of catheter-related infections in haemodialysis patients. Nephrol Dial Transplant 2001; 16:1975-1978.
4. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use. Kidney Int 2000; 58:2543-2545.
5. Nielsen J, Ladefoged SD, Kolmos HJJ. Dialysis catheter-related septicemia: Focus on Staphylococcus aureus septicemia. Nephrol Dial Transplant 1998; 13:2847-2852.
6. Marr KA, Sexton DJ, Conlon PJ, Corey GR, Schwab SJ, Kirkland KB. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127:275-280.
7. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:869-876.
8. Taylor GD, McKenzie M, Buchanan-Chell M, Caballo L, Chiu L, Kowalewska-Grochowska K. Central venous catheters as a source of hemodialysis-related bacteremia. Infect Control Hosp Epidemiol 1998; 19:643-646.
9. Sesso R, Barbosa D, Leme IL, Sader H, Caziana M, Manfredi S, Draibe S, Pignatari AC. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheters: Effect of mupirocin ointment. J Am Soc Nephrol 1998; 9:1085-1092.
10. Little MA, O'Riordan AO, Lucey B, Farrell M, Lee M, Conlon PJ, Walshe JJ. A prospective study of complications associated with cuffed tunnelled hemodialysis catheters. Nephrol Dial Transplant 2001; 16:2194-2200.
11. Nielsen J, Kolmos H, Espersen F. Staphylococcus aureus bacteremia among patients undergoing dialysis: Focus on dialysis catheter-related cases. Nephrot Dial Transplant 1998; 13:139-145.
12. Siegman-Igra Y, Golan H, Schwartz D, Cahaner Y, De Mayo G, Orni-Wasserlauf R. Epidemiology of vascular catheter-related bloodstream infections in a large University hospital in Israel. Scand J Infect Dis 2000; 32:411-415.
13. Dhingra RK, Young EW, Hulpert-Shearon TE, Leavey SF, Port F. Type of vascular access and mortality in US hemodialysis patients. Kidney Int 2001; 60:1443-1451.
14. Casewell MW, Hill RLR. In vitro activity of mupirocin (pseudomonic acid) against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985; 17:523-531.
15. Casewell MW, Hill RLR. Elimination of nasal carriage Staphylococcus aureus with mupirocin (pseudomonic acid): A controlled trial. J Antimicrob Chemother 1986; 17:365-372.
16. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol 1989; 20:1083-1087.
17. Bernardini JB, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral Rifampin. Am J Kidney Dis 1996; 27:695-700.
18. Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18:261-270.
19. Casey M, Taylor J, Clinard P, Graham P, Mauck V, Spainhour L, Brown P, Burkart J. Application of mupirocin cream at the catheter site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 2000; 20:566-568.
20. Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Adeva M, Rodriguez-Lozano I, Moncalian J. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: Long-term results. Am J Kidney Dis 1993; 22:708-712.
21. The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996; 7:2403-2408.
22. Boelart JR, Van Landuyt HW, Godard CA, Daneels RF, Schurgers ML, Matthys EG, De Baere YA, Gheyle DW, Gordts BZ, Herwaldt LA. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteremias in haemodialysis patients. Nephrol Dial Transplant 1993; 8:235-239.
23. Hill RLR, Fisher AP, Ware RJ, Wilson S, Casewell MW. Mupirocin for the reduction of internal jugular cannulae: A randomized control trial. J Hosp Infect 1990; 15:311-321.
24. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Garcia-Falcon T, Valdez F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39:337-341.
25. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, Jassal V, Oreopoulos D. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:554-559.
26. Rao SP, Oreopoulos DG. Unusual complication of a polyurethane PD catheter [Letter]. Perit Dial Int 1997; 17:410-412.
27. Rui S, Ruiz CG, Martinez Vera A, Peralta C, Oliver JA. Spontaneous rupture of polyurethane peritoneal catheter: A possible deleterious effect of mupirocin ointment. Nephrol Dial Transplant 1998; 13:1870-1871.
28. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391-402.
29. Levin A, Mason J, Jindal KK, Fong W, Goldstein MB. Prevention of hemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int 1991; 40:934-938.
30. Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM, Hollett P. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17:1802-1807.